RESUMEN
OBJECTIVES: Our objective was to evaluate the pharmacokinetics of nelfinavir (NFV) (625 mg tablets) 1250 mg twice daily during pregnancy and postpartum. METHODS: The participants were HIV-1-infected pregnant women enrolled in P1026s and receiving NFV (625 mg tablets) 1250 mg twice daily as part of routine clinical care. Intensive steady-state 12-h NFV pharmacokinetic profiles were performed during pregnancy and postpartum. The target NFV area under the plasma concentration-time curve (AUC(0-12)) was >or=10th percentile NFV AUC(0-12) in non-pregnant historical controls (18.5 microg h/mL). RESULTS: Of 27 patients receiving NFV, pharmacokinetic data were available for four (second trimester), 27 (third trimester) and 22 (postpartum) patients. The NFV maximum concentration (C(max)), 12-h post-dose concentration (C(12)) and AUC(0-12) were significantly lower during the third trimester compared to postpartum (PAsunto(s)
Infecciones por VIH/tratamiento farmacológico
, Inhibidores de la Proteasa del VIH/farmacocinética
, VIH-1
, Nelfinavir/farmacocinética
, Complicaciones Infecciosas del Embarazo/tratamiento farmacológico
, Adolescente
, Adulto
, Área Bajo la Curva
, Recuento de Linfocito CD4
, Esquema de Medicación
, Femenino
, Infecciones por VIH/metabolismo
, Inhibidores de la Proteasa del VIH/administración & dosificación
, Humanos
, Recién Nacido
, Nelfinavir/administración & dosificación
, Embarazo
, Complicaciones Infecciosas del Embarazo/metabolismo
, Infección Puerperal/tratamiento farmacológico
, Infección Puerperal/metabolismo
, ARN Viral
, Carga Viral
, Adulto Joven